基于大健康的医药产业发展能力评价指标体系构建初探

摘要

Objective:To investigate the construction of the evaluation index system of the development ability of pharmaceutical industry based on Big Health,and to provide the reference for analyzing and evaluating the sustainable development ability of pharmaceutical industry.Methods:Taking Ethonmedicine industry,small molecular chemical industry,biological products industry,medical equipment industry and medical derivatives industry as research subjects,combined with literature re view and seminar discussion to determine targeting indexs and reference weight of each subindustry index system,the rationality and feasibility of the index system.Results:All constructed index systems are tree structure,including primary and secondary indexes.Six primary indexes of each subindustry's index system are the same.They are return on investment,research and development,manufacturing capability,marketing,organizing and administration and social benefits.Reference weight placed return on investment as the highest one,reserch and development as secondary and social benefits as the lowest.Secondary indexes are different,quantitative indexes reference weight showed return on investment as the highest,research development as secondadry,social benefits as the lowest qualitative indexes.It was tested that the ratio of the evaluation results of each index system to the objective fact was 100％,which proved the rationality and feasibility of such system.Conclusions:Indexes and reference weight concluded in index systems conform to the development trend and characteristics of pharmaceutical industry.%目的:初步构建基于大健康的医药产业发展能力评价指标体系,为分析医药产业的可持续发展能力提供依据.方法:以医药产业的中药民族药产业、小分子化学药产业、生物制品产业、医疗器械产业及医药衍生品产业的5个子产业为研究对象,通过查阅文献结合召开专题小组讨论会的方式确定各子产业指标体系的纳入指标及参考权重,并采用调查方式对构建的指标体系进行测评,评价其合理性和可行性.结果:医药产业的5个子产业构建的指标体系为树形结构,包括一级指标和二级指标;各子产业指标体系6个一级指标相同,分别是资源投入回报能力、研究开发能力、生产制造能力、市场营销能力、组织管理能力及社会效益能力;参考权重为资源投入回报能力最高,其次为研究开发能力,社会效益能力最低;而纳入的二级指标不同,包括定量指标参考权重为资源投入回报能力最高,其次为研究开发能力,社会效益能力最低定性指标,二级指标的参考权重不同;经实测,各指标体系评价结果与客观事实相符合的比率均为100％,提示所建立的指标体系具有合理性和可行性.结论:初步构建的指标体系所纳入指标及参考权重符合医药产业发展趋势、特点.